Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Weight-Bearing CT’s Role in Assessing Pes Cavovarus

Dr. Alessio Bernasconi, MD, FEBOT and  his colleagues at the Royal National Orthopaedic Hospital in London have produced critical and salient findings about the role of weight-bearing CT imaging (WBCT) in assessing pes cavovarus. Dr. Bernasconi recently shared these findings in a FOOTinnovate webinar, and his presentation is outlined below. Click here to watch the FOOTInnovate…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Dr. Alessio Bernasconi, MD, FEBOT and his colleagues at the Royal National Orthopaedic Hospital in London have produced critical and salient findings about the role of weight-bearing CT imaging (WBCT) in assessing pes cavovarus.

Dr. Bernasconi recently shared these findings in a FOOTinnovate webinar, and his presentation is outlined below.

Click here to watch the FOOTInnovate webinar. A FOOTInnovate account is required.

A Refresher on Pes Cavovarus Diagnosing Procedures

Pes cavovarus is considered a three-dimensional deformity and is characterized by a high-arched, varus hindfoot alignment with a forefoot that may be abducted or plantarflexed depending on the individual case.

Diagnostic work for pes cavovarus is based on a thorough clinical assessment. However, additional imaging is needed, and X-Ray imaging is the current standard. Additional CT or MRI imaging can be ordered to further characterize the deformity and assess the status of joints and soft tissues.

However, common dorsoplantar, lateral views of bilateral cavovarus deformity can bring along with them difficulty in precisely identifying joint planes and status. Recent studies, including published papers from PubMed suggest that radiographs have inherent bias as beam position, operators, foot position, and more can change what doctors see and identify.

Is there any objective way to identify hindfoot alignment?

Improving Identification of Hindfoot Alignment

The Saltzman view – developed by Charles Saltzman, MD and Georges El-Khoury, MD – is designed to find the main axis of the tibia and the main axis of the calcaneus, then to define the angle between those two lines.

However, this view can still be limited by rotation of the foot.

That’s why authors like Jonathan Kaplan, MD, who outlined a solution in Foot & Ankle International, propose the use of weight-bearing CT scanning as a better alternative when diagnosing malalignment associated with pes cavovarus.

The Implications of Weight-Bearing CT Scanning

Two studies published in 2017 and 2018 introduced the idea of using three-dimensional measurements on weight-bearing CT images, allowing the measurement of malalignment to move away from a single plane and toward a volume-based view that produces a more reliable and true view of the bones in physical space.

The three measurements proposed are foot and ankle offsets, the calcaneal offset and the hindfoot alignment angle.

In 2017, a study assessing 135 datasets including normally aligned feet, varus hindfeet and valgus hindfeet demonstrated excellent inter and intra-observer reliability using this new measurement.

The true revolution in utilizing 3D measurements is that, in gathering the three measurements, you can add a fourth point to represent volume that provides that additional beneficial depth.

“What you need is a cone-beam, weight-bearing CT device,” Dr. Bernasconi said. “In our institution, we use the PedCAT one. You need a software to elaborate data – CubeVue – and you need a TALAS plug-in.”

Essentially, Dr. Bernasconi said, this landmark software solution can provide a simpler way to obtain values relative to the normative values that highlight varus or valgus malalignment.

Critical Questions

Dr. Bernasconi highlighted three critical questions regarding the reliability of this new solution:

  • How reliable are 3D measurements when diagnosing pes cavovarus?
  • Does etiology affect reliability?
  • Does the severity of the deformity affect reliability?

To find the answers, Dr. Bernasconi and the staff at the Royal National Orthopaedic Hospital completed a retrospective study based on STROBE guidelines of patients with a pes cavovarus diagnosis from their hospital between 2015 and 2017.

Eventually settling on 17 patients, the team matched those patients with an equal number of normally aligned feet. Three observers with different levels of expertise and different knowledge of the weight-bearing CT imaging process produced excellent inter-observer reliability. Further, there was little variance between the observers, suggesting that the data is reliable regardless of previous expertise, etiology and deformity severity.

“The reason that we have studied foot morphology, thanks to the help, obviously, of this new technology, (is that) standing CT allows you to reproduce in a more faithful way the true geometry of the bone and the joints in the space,” Dr. Bernasconi said. “We think that this may potentially help us better understand the etiology.”

Though Dr. Bernasconi said his findings were far from enough to fully corroborate this positive outcome, they are certainly a starting point.

The takeaway, he said, is that this new, 3D approach will allow for reliable assessment of pes cavovarus, both in the diagnosing stage and in monitoring patients after procedures to determine how successful the correction was.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512